About the project

The project focuses on the preclinical development of a safe and efficient prophylactic and therapeutic DNA vaccine ready for clinical trials against different forms of leishmaniasis. The immunogenicity of our T cell-directed vaccine LEISHDNAVAX, will be evaluated in human cell culture systems, its efficacy will be determined in models for visceral and cutaneous leishmaniasis, and we will establish its safety in standardised preclinical studies.

The vaccine will be based on the Minimalistic Immunogenically Defined Gene Expression (MIDGE) vector developed for efficient induction of T-cellular immune responses and, if required, adjuvanted with Double Stem Loop Immunomodulator (dSLIM). These technologies have been developed by Mologen AG ( http://www.mologen.com ), our SME partner.

Project structure